Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
The discussions are expected to pave the way for the creation of a consolidated national knowledge-sharing platform on IT-enabled Ayush services,
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
The company is bringing precision therapies for gynaecological cancers
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
AINU is set to accelerate its expansion footprint, enhance operational capabilities
Subscribe To Our Newsletter & Stay Updated
